Delphi Consensus Meeting on Tuesday 26th September 2023 at 7pm (BST)

You may be aware that there is some concern about the compatibility of certain brands of folinic acid with oxaliplatin. A group of pharmacists, on behalf of the British Oncology Pharmacy Association would like to develop a national consensus on the best approach to handling this situation.

They are planning to hold an on-line delphi consensus meeting on Tuesday 26th September 2023 at 7pm (BST). The aim is to review the published information and then (if possible) to reach a consensus. We are looking for UK based:

  • Pharmacists & Pharmacy Technicians with clinical backgrounds where infusional fluorouracil with folinic acid are routinely used
  • Pharmacists & Pharmacy Technicians or other experts from Quality Assurance, Quality Control, Health Informatics and Aseptic backgrounds
  • Pharmacists or Pharmacy Technicians with involvement in medicines procurement
  • Medication Safety Officers
  • Medical or clinical oncologists with significant experience in the design of folinic acid based chemotherapy protocols
  • Other multi-disciplinary team members, including chemotherapy nurses, with relevant expertise

to participate in an on-line meeting lasting up to 90 minutes. The meeting will present an overview of the available data and present a number of proposed solutions to be considered by the audience. The audience will be expected to participate in a series of votes during the meeting. Participation is open to BOPA and non-BOPA members.

The purpose of the meeting would be to produce a document that can be published.

If you would be willing to participate please complete the online registration form here:
https://forms.office.com/e/N1fxvCymex

Participants will be contacted by email with further information nearer the time including login details for the meeting and some pre-reading materials.

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article